Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver Sells 1,586 Shares

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver sold 1,586 shares of the business’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $10.85, for a total transaction of $17,208.10. Following the completion of the sale, the chief financial officer now owns 146,916 shares of the company’s stock, valued at $1,594,038.60. The trade was a 1.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Evolus Stock Performance

NASDAQ:EOLS opened at $11.35 on Friday. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The firm’s 50-day moving average is $13.56 and its 200-day moving average is $13.75. Evolus, Inc. has a 52-week low of $9.80 and a 52-week high of $17.82. The company has a market cap of $718.69 million, a price-to-earnings ratio of -12.47 and a beta of 1.27.

Hedge Funds Weigh In On Evolus

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its holdings in shares of Evolus by 173.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock worth $6,781,000 after purchasing an additional 265,635 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Evolus by 24.6% during the second quarter. Bank of New York Mellon Corp now owns 181,093 shares of the company’s stock worth $1,965,000 after buying an additional 35,760 shares in the last quarter. Armistice Capital LLC acquired a new stake in Evolus during the second quarter worth $3,906,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Evolus in the 3rd quarter valued at $940,000. Finally, Lord Abbett & CO. LLC lifted its holdings in shares of Evolus by 23.4% during the 3rd quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock worth $16,126,000 after acquiring an additional 188,685 shares during the period. 90.69% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on EOLS. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Evolus in a report on Thursday, November 7th. Barclays boosted their price objective on Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Evolus in a report on Friday, September 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a report on Monday, September 16th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.